{"id":1537,"date":"2018-04-13T15:13:33","date_gmt":"2018-04-13T14:13:33","guid":{"rendered":"https:\/\/www.groupactionlawyers.co.uk\/blog\/?p=1537"},"modified":"2018-04-13T15:13:33","modified_gmt":"2018-04-13T14:13:33","slug":"lynparza-cancer-drug-recall-confirmed-by-uk-regulators","status":"publish","type":"post","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators","title":{"rendered":"Cancer drug recall confirmed by UK regulators"},"content":{"rendered":"

A cancer drug recall has been initiated due to reports of excessive levels of an active ingredient used in the drug.<\/p>\n

Pharmaceutical company AstraZeneca UK has initiated the recall, primarily for batch NG327, because the “level of olaparib polymorphic form L exceeds the registered specification limit”.<\/p>\n

As well as the batch being recalled above, there are other batches that are a part of the recall as well, which is all said to be a part of a precautionary measure.
\n
\nWe don’t need to go into any detail as to how important cancer drugs are. Cancer remains one of the big problems that humanity is still trying to overcome, and thanks to key developments over the last few decades which have led to the use of drugs that can halt the spread of cancer and potentially save lives.<\/p>\n

Any medical product recall can be seen as serious, but a cancer drug recall is certainly an issue that is worrisome. The product manufacturer states that “there is no safety risk to patients taking Lynparza capsules containing any level of polymorphic Form L”<\/a> which suggests there is no need to worry, and they state that the recall is a precautionary measure only.<\/p>\n

Still, a problem with a cancer drug could be concerning for patients.<\/p>\n

Healthcare organisations are being asked to stop dispensing the drug<\/strong> from the list of affected batches, and to return all remaining stock to their suppliers. Generic product monitoring has reportedly uncovered the issue, leading to the Class 3 Medicines Recall<\/a> being initiated.<\/p>\n

With this being a cancer drug recall, it’s a situation we will be keeping an eye on. <\/p>\n

We hope the advice from AstraZeneca UK that there is no risk to patient safety remains the case.<\/p>\n","protected":false},"excerpt":{"rendered":"

A cancer drug recall has been initiated due to reports of excessive levels of an active ingredient used in the drug. Pharmaceutical company AstraZeneca UK has initiated the recall, primarily for batch NG327, because the “level of olaparib polymorphic form L exceeds the registered specification limit”. As well as the batch being recalled above, there … Continue reading Cancer drug recall confirmed by UK regulators<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":1539,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"AstraZeneca UK has initiated a Class 3 cancer drug recall for Lynparza capsules (50mg) with batch numbers NG327.\r\n\r\nAs a precautionary measure additional batches are also being recalled (EL(18)A\/06).","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[5,27],"tags":[62,60,61],"class_list":["post-1537","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medical","category-products","tag-cancer-drug","tag-medical-product","tag-medical-recall"],"yoast_head":"\nLynparza Cancer Drug Recall Confirmed By UK Regulators<\/title>\n<meta name=\"description\" content=\"A Class 3 recall has been initiated for Lynparza capsule (50mg) due to reports of excessive levels of an active ingredient used in the drug. AstraZeneca UK has initiated the cancer drug recall, primarily for batch NG327.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.groupactionlawyers.co.uk\/blog\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lynparza Cancer Drug Recall Confirmed By UK Regulators\" \/>\n<meta property=\"og:description\" content=\"A Class 3 recall has been initiated for Lynparza capsule (50mg) due to reports of excessive levels of an active ingredient used in the drug. AstraZeneca UK has initiated the cancer drug recall, primarily for batch NG327.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.groupactionlawyers.co.uk\/blog\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators\" \/>\n<meta property=\"og:site_name\" content=\"Group Action Lawyers\" \/>\n<meta property=\"article:published_time\" content=\"2018-04-13T14:13:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i2.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/cancer-drug-recall-facebook.png?fit=1200%2C630&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Author\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/cancer-drug-recall-twitter.png?fit=1024%2C512&ssl=1\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Author\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators\"},\"author\":{\"name\":\"Author\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/#\\\/schema\\\/person\\\/0203ba576ea8f4e8ec318e9677b2a84b\"},\"headline\":\"Cancer drug recall confirmed by UK regulators\",\"datePublished\":\"2018-04-13T14:13:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators\"},\"wordCount\":296,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.groupactionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/cancer-drug-recall.png?fit=1200%2C414&ssl=1\",\"keywords\":[\"cancer drug\",\"medical product\",\"medical recall\"],\"articleSection\":[\"Medical\",\"Products\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators\",\"url\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators\",\"name\":\"Lynparza Cancer Drug Recall Confirmed By UK Regulators\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.groupactionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/cancer-drug-recall.png?fit=1200%2C414&ssl=1\",\"datePublished\":\"2018-04-13T14:13:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/#\\\/schema\\\/person\\\/0203ba576ea8f4e8ec318e9677b2a84b\"},\"description\":\"A Class 3 recall has been initiated for Lynparza capsule (50mg) due to reports of excessive levels of an active ingredient used in the drug. AstraZeneca UK has initiated the cancer drug recall, primarily for batch NG327.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/www.groupactionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/cancer-drug-recall.png?fit=1200%2C414&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.groupactionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/cancer-drug-recall.png?fit=1200%2C414&ssl=1\",\"width\":\"1200\",\"height\":\"414\",\"caption\":\"drug recall\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cancer drug recall confirmed by UK regulators\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/\",\"name\":\"Group Action Lawyers\",\"description\":\"Latest Legal News, Articles & Opinions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/#\\\/schema\\\/person\\\/0203ba576ea8f4e8ec318e9677b2a84b\",\"name\":\"Author\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/538ab826f4f2d4a28667f572267412a34ffb2abdd54a9fe5d344f0d525bf201f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/538ab826f4f2d4a28667f572267412a34ffb2abdd54a9fe5d344f0d525bf201f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/538ab826f4f2d4a28667f572267412a34ffb2abdd54a9fe5d344f0d525bf201f?s=96&d=mm&r=g\",\"caption\":\"Author\"},\"url\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/author\\\/matt\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lynparza Cancer Drug Recall Confirmed By UK Regulators","description":"A Class 3 recall has been initiated for Lynparza capsule (50mg) due to reports of excessive levels of an active ingredient used in the drug. AstraZeneca UK has initiated the cancer drug recall, primarily for batch NG327.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.groupactionlawyers.co.uk\/blog\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators","og_locale":"en_GB","og_type":"article","og_title":"Lynparza Cancer Drug Recall Confirmed By UK Regulators","og_description":"A Class 3 recall has been initiated for Lynparza capsule (50mg) due to reports of excessive levels of an active ingredient used in the drug. AstraZeneca UK has initiated the cancer drug recall, primarily for batch NG327.","og_url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators","og_site_name":"Group Action Lawyers","article_published_time":"2018-04-13T14:13:33+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/i2.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/cancer-drug-recall-facebook.png?fit=1200%2C630&ssl=1","type":"image\/png"}],"author":"Author","twitter_card":"summary_large_image","twitter_image":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/cancer-drug-recall-twitter.png?fit=1024%2C512&ssl=1","twitter_misc":{"Written by":"Author","Estimated reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators#article","isPartOf":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators"},"author":{"name":"Author","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/#\/schema\/person\/0203ba576ea8f4e8ec318e9677b2a84b"},"headline":"Cancer drug recall confirmed by UK regulators","datePublished":"2018-04-13T14:13:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators"},"wordCount":296,"commentCount":0,"image":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/cancer-drug-recall.png?fit=1200%2C414&ssl=1","keywords":["cancer drug","medical product","medical recall"],"articleSection":["Medical","Products"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.groupactionlawyers.co.uk\/blog\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators","url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators","name":"Lynparza Cancer Drug Recall Confirmed By UK Regulators","isPartOf":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators#primaryimage"},"image":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/cancer-drug-recall.png?fit=1200%2C414&ssl=1","datePublished":"2018-04-13T14:13:33+00:00","author":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/#\/schema\/person\/0203ba576ea8f4e8ec318e9677b2a84b"},"description":"A Class 3 recall has been initiated for Lynparza capsule (50mg) due to reports of excessive levels of an active ingredient used in the drug. AstraZeneca UK has initiated the cancer drug recall, primarily for batch NG327.","breadcrumb":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.groupactionlawyers.co.uk\/blog\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators#primaryimage","url":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/cancer-drug-recall.png?fit=1200%2C414&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/cancer-drug-recall.png?fit=1200%2C414&ssl=1","width":"1200","height":"414","caption":"drug recall"},{"@type":"BreadcrumbList","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/lynparza-cancer-drug-recall-confirmed-by-uk-regulators#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.groupactionlawyers.co.uk\/blog"},{"@type":"ListItem","position":2,"name":"Cancer drug recall confirmed by UK regulators"}]},{"@type":"WebSite","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/#website","url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/","name":"Group Action Lawyers","description":"Latest Legal News, Articles & Opinions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.groupactionlawyers.co.uk\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/#\/schema\/person\/0203ba576ea8f4e8ec318e9677b2a84b","name":"Author","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/538ab826f4f2d4a28667f572267412a34ffb2abdd54a9fe5d344f0d525bf201f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/538ab826f4f2d4a28667f572267412a34ffb2abdd54a9fe5d344f0d525bf201f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/538ab826f4f2d4a28667f572267412a34ffb2abdd54a9fe5d344f0d525bf201f?s=96&d=mm&r=g","caption":"Author"},"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/author\/matt"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/cancer-drug-recall.png?fit=1200%2C414&ssl=1","jetpack-related-posts":[{"id":838,"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/alvogen-recalls-24-lots-hypertension-due-chemical-contamination","url_meta":{"origin":1537,"position":0},"title":"Alvogen recalls 24 lots of hypertension drug off the market due to chemical contamination","author":"Admin","date":"24th July 2017","format":false,"excerpt":"A medical drug manufacturer has initiated a voluntary recall on 3rd July 2017 after concerns their Nifedipine tablets have become contaminated with other medication ingredients. The company, based in Iceland, makes the hypertension drug under the brand name Adalat, which is supplied to Bayer HeathCare. It's used for channel blocking\u2026","rel":"","context":"In "Medical"","block_context":{"text":"Medical","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/category\/medical"},"img":{"alt_text":"drugs","src":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/drugs-recall-750x250.png?fit=750%2C250&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/drugs-recall-750x250.png?fit=750%2C250&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/drugs-recall-750x250.png?fit=750%2C250&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/drugs-recall-750x250.png?fit=750%2C250&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":1750,"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/are-you-suffering-with-valsartan-side-effects","url_meta":{"origin":1537,"position":1},"title":"Are you suffering with valsartan side effects?","author":"Author","date":"25th March 2019","format":false,"excerpt":"If you\u2019re suffering with valsartan side effects, you may want to read this article and take heed of some important information about the drug. Last year, a Class 1 Medicines Recall was initiated by Medicines and Healthcare products Regulatory Agency (MHRA). The recall stems from potential contamination that comes from\u2026","rel":"","context":"In "Latest"","block_context":{"text":"Latest","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/category\/latest"},"img":{"alt_text":"drugs alert","src":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/antibiotics-alert-min.png?fit=725%2C250&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/antibiotics-alert-min.png?fit=725%2C250&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/antibiotics-alert-min.png?fit=725%2C250&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/antibiotics-alert-min.png?fit=725%2C250&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":234,"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/teva-uk-ltd-has-recalled-progestogen-only-pill-drug","url_meta":{"origin":1537,"position":2},"title":"“Progestogen-only Pill Drug Recalls” – Teva UK Ltd has recalled drugs due to impurities showing in their routine testing","author":"Author","date":"17th November 2016","format":false,"excerpt":"Teva UK Limited are one of the latest pharmaceutical manufacturers that have recalled a batch of their drugs. The Nacrez 75 mg film-coated tablets have been recalled due to impurities found as part of their routine testing. The recall is said to be a precautionary measure taken by the company\u2026","rel":"","context":"In "Medical"","block_context":{"text":"Medical","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/category\/medical"},"img":{"alt_text":"drugs","src":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/drugs-recall-750x250.png?fit=750%2C250&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/drugs-recall-750x250.png?fit=750%2C250&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/drugs-recall-750x250.png?fit=750%2C250&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/drugs-recall-750x250.png?fit=750%2C250&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":849,"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/diclo-sr-75-pain-relief-tablets-class-2-recall","url_meta":{"origin":1537,"position":3},"title":"Class 2 recall for Diclo-SR 75 pain-relief tablets","author":"Admin","date":"28th July 2017","format":false,"excerpt":"A Watford-based pharmaceutical company has issued a voluntary recall for batches of Diclo-SR 75 pain relief tablets - AKA diclofenac sodium. The tablets are commonly used for pain relief and swelling for arthritis, musculoskeletal disorders, gout and pain caused by injury or minor surgery. The tablets are classified in a\u2026","rel":"","context":"In "Medical"","block_context":{"text":"Medical","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/category\/medical"},"img":{"alt_text":"pain relief tablets recall","src":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/pain-relief-tablets-recall-min.png?fit=725%2C250&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/pain-relief-tablets-recall-min.png?fit=725%2C250&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/pain-relief-tablets-recall-min.png?fit=725%2C250&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/pain-relief-tablets-recall-min.png?fit=725%2C250&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":1821,"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/drugs-recall-compensation-claims-advice","url_meta":{"origin":1537,"position":4},"title":"Drugs recall compensation claims advice","author":"Author","date":"2nd September 2019","format":false,"excerpt":"Drugs recall compensation claims can form into group and multi-party actions when users have suffered as a result of a problem with the manufacturers or the suppliers. The impact for the victims in these kinds of cases can, of course, be severe; especially if the drugs being recalled are for\u2026","rel":"","context":"In "Group Actions"","block_context":{"text":"Group Actions","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/category\/group-actions"},"img":{"alt_text":"liver disease drug warning","src":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/liver-disease-drug-warning-min.png?fit=725%2C250&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/liver-disease-drug-warning-min.png?fit=725%2C250&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/liver-disease-drug-warning-min.png?fit=725%2C250&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/liver-disease-drug-warning-min.png?fit=725%2C250&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":1652,"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/latanoprost-timolol-eye-drops-recall","url_meta":{"origin":1537,"position":5},"title":"Latanoprost Timolol eye drops recall","author":"Author","date":"7th September 2018","format":false,"excerpt":"A Latanoprost Timolol eye drops recall has been announced by the Medicines and Healthcare Regulatory Authority (MHRA). The company behind the eye drops, FDC Pharma, are recalling a batch due to what has been classed as an \u2018out of specification result for an unknown impurity\u2019 that was identified during testing.\u2026","rel":"","context":"In "Medical"","block_context":{"text":"Medical","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/category\/medical"},"img":{"alt_text":"eye claims","src":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2017\/01\/hoya-optics-recall.png?fit=725%2C250&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2017\/01\/hoya-optics-recall.png?fit=725%2C250&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2017\/01\/hoya-optics-recall.png?fit=725%2C250&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2017\/01\/hoya-optics-recall.png?fit=725%2C250&ssl=1&resize=700%2C400 2x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts\/1537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/comments?post=1537"}],"version-history":[{"count":2,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts\/1537\/revisions"}],"predecessor-version":[{"id":1542,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts\/1537\/revisions\/1542"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/media\/1539"}],"wp:attachment":[{"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/media?parent=1537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/categories?post=1537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/tags?post=1537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}